Abstracts tagged "patient outcomes and psoriatic arthritis"

Abstract Number: 676 • 2018 ACR/ARHP Annual Meeting
A Novel Role for the Psoriatic Arthritis Impact of Disease Questionnaire
Kishor Johnson¹, Justine Y. Ye², Vinod Chandran² and Dafna D Gladman², ¹Western University, London, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in about 30% of patients with Psoriasis (Ps). Recently, a new Patient Reported Outcome Measure…
Abstract Number: 1659 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results
Roy Fleischmann¹, Vinod Chandran², Eric Lespessailles³, Julie Birt⁴, Olivier Benichou⁴, Janelle Erickson⁴ and Catherine Shuler⁴, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Krembil Research Institute and University of Toronto, Toronto, ON, Canada, ³University of Orléans, Orléans, France, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements compared to placebo not only in disease activity but also in various…
Abstract Number: 2566 • 2018 ACR/ARHP Annual Meeting
Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study
Luis Puig¹, Chenglong Han², Ronald Vender³, Michael Song², Yin You², Yaung-Kaung Shen² and Peter Foley⁴, ¹Hospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona Medical School, Barcelona, Spain, ²Janssen Research & Development, LLC, Spring House, PA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc., Carlton, Australia
Background/Purpose: VOYAGE 2 is a phase 3 double-blind, placebo/active comparator-controlled trial comparing guselkumab (GUS) with placebo (PBO) and adalimumab (ADA) in patients (pts) with moderate-to-severe…
Abstract Number: 335 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Patients Who Attain a Very Low Disease Activity State Have a Minimal Impact of the Disease on Their Lives
Rubén Queiro¹, Juan D. Cañete², Carlos Alberto Montilla-Morales³, Miguel A. Abad⁴, Susana Gomez Castro⁵ and Ana Cabez⁵, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology, HU. Virgen del Puerto., Plasencia, Spain, ⁵Pfizer, Madrid, Spain
Background/Purpose: The target of treatment in psoriatic arthritis (PsA) should be remission or inactive disease. A potential definition that would fit with the Treat-to-Target Recommendations…
Abstract Number: 346 • 2017 ACR/ARHP Annual Meeting
What Are We Measuring? Influence of Contextual Factors on RAPID3 Scores in Psoriatic Arthritis
Alexis Ogdie¹, Christine Willinger², M. Elaine Husni³, Jose U. Scher⁴, Soumya M. Reddy⁵ and Jessica A. Walsh⁶, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Cleveland Clinic, Cleveland, OH, ⁴New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ⁶Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Patient reported outcomes (PRO) provide valuable insights into patientsÕ perceptions of their disease and overall health and function, and these perceptions influence management of…
Abstract Number: 2553 • 2017 ACR/ARHP Annual Meeting
Patient and Physician Global Assessment Are Poorly Inter-Connected and Poorly Explained By Other Clinical Markers of Disease Activity in Individual Patients with Psoriatic Arthritis
Ole Rintek Madsen, Center for Rheumatology and Spine Diseases & The DANBIO Registry, Copenhagen University Hospital Rigshospitalet Gentofte and Glostrup, Denmark, Hellerup, Denmark
Background/Purpose: Assessment of disease activity is important in the evaluation and monitoring of patients with psoriatic arthritis (PsA) in clinical care and research. As there…
Abstract Number: 2173 • 2016 ACR/ARHP Annual Meeting
Patient Reported Disease Activity and Efficacy of Biologic Therapy in Patients with Psoriatic Arthritis. an Observational Study of 107 Patients of the Estonian Society for Rheumatology Biologic Therapy Register during 2008-2014
Sandra Tälli¹, Marika Tammaru² and Kati Otsa¹, ¹East-Tallinn Central Hospital, Department of Rheumatology, MD, Tallinn, Estonia, ²East-Tallinn Central Hospital, MD, PhD, Tallinn, Estonia
Background/Purpose: Psoriatic arthritis is a heterogenous disease that can effectively be treated with biologic therapy. The treatment outcome is affected by difference in disease expression…
Abstract Number: 2741 • 2016 ACR/ARHP Annual Meeting
Reliability and Construct Validity of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire – Independent Validation Study in a UK Cohort
Richard Holland¹, William Tillett^1,2, Eleanor Korendowych¹, Charlotte Cavill^1,3, Mel Brooke⁴ and Neil J McHugh⁵, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Rheumatology, Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁴PsAZZ Support Group, Bath, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases and Dept Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Patient reported outcomes (PROs) have been found to be reliable indicators of baseline status, change during treatment, and are predictive of long-term outcome. A…
Abstract Number: 656 • 2015 ACR/ARHP Annual Meeting
Convergent Construct Validity of PsAID12 in a Psoriatic Arthritis Cohort at Baseline
Umut Kalyoncu^1,2, Levent Kilic¹, Abdulsamet Erden¹, Omer Karadag¹, Sule Apras Bilgen¹, Sedat Kiraz¹, Ihsan Ertenli¹, Clifton Bingham³ and Ana-Maria Orbai², ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: The Psoriatic Arthritis Impact of Disease (PsAID) PRO measure was developed for clinical trials (9 item) and routine care (12 item) in Psoriatic arthritis…
Abstract Number: 2336 • 2015 ACR/ARHP Annual Meeting
Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Steffen Jugl¹, Sultana Syeda² and Gunda Praveen², ¹BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland, ²Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India
Background/Purpose: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic progressive conditions with substantial humanistic burden on patients and care givers. A variety of instruments,…
Abstract Number: 1584 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis
Pinar Cetin¹, Dilek Solmaz², Murat Keser³, Ismail Sari¹, Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, ³Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being, which was used in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].